Loading data for RNXT — first visit, this takes a few seconds.

알림

RenovoRx Inc. (RNXT)

NasdaqCM: RNXT · 실시간 가격 · USD

1.40

+0.14 (11.11%)

종가 기준: Aug 19, 2026, 8:00 PM

1.30

-1.14%

애프터마켓: 4:33 PM

11.11% (1D)

데이터 없음

매수호가	1.02
시가총액	59.35M
매출 (ttm)	1.98M
순이익 (ttm)	-12.29M
베타	0.99
EPS (ttm)	-0.31
P/E (ttm)	n/a
선행 P/E	-8.48
P/B (ttm)	6.61
P/S (ttm)	30.03
Earnings Date	Aug 14, 2025

매도호가	1.62
거래량	1,001,657
평균 거래량 (20일)	294,308
시가	1.27
전일 종가	1.26
일중 범위	1.26 - 1.45
52주 범위	0.70 - 1.45
애널리스트	n/a
목표주가	n/a
배당	n/a
배당락일	n/a

RNXT 소개

RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in developing targeted combination therapies to improve therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. The company was founded in 2009 and is headquartered in Mountain View, Calif...

[더 보기]

산업 Biotechnology

섹터 Healthcare

IPO 일자 Aug 26, 2021

직원 수 17

상장 거래소 NasdaqCM

티커 RNXT

웹사이트 https://renovorx.com

전체 기업 정보

재무 실적

2025년 RenovoRx의 매출은 1.12M로, 전년 43K 대비 2,511.63% 증가했습니다. 순이익은 -11.17M로, 26.71% 증가했습니다.

재무제표

어닝 서프라이즈

RenovoRx가 May 14, 2026에 분기 실적을 발표했습니다:

매출 $563K 예상치 하회 $0, 및 185.79% 전년 대비 성장.

EPS -0.08 예상치 하회 0.00, 및 0.00% 전년 대비 성장.

다음 실적 발표

RenovoRx Inc.의 실적 발표 예정일은 Aug 14, 2025, 장 마감 후입니다.
애널리스트 예상 매출은 ... 업그레이드

뉴스

1주 전 · Zacks

Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Misses Revenue Estimates

Bolt Biotherapeutics (BOLT) delivered earnings and revenue surprises of -53.87% and -99.67%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1주 전 · Benzinga

EXCLUSIVE: Renovorx Advances Its Targeted Pancreatic Cancer Therapy, Pivotal Data Expected in 2027

RenovoRx, Inc. (NASDAQ:RNXT) announced Tuesday that it has completed patient enrollment for its Phase 3 TIGeR-PaC study of its targeted drug delivery platform for locally advanced pancreatic cancer (L...

1주 전 · Zacks

Enanta Pharmaceuticals (ENTA) Reports Q3 Loss, Lags Revenue Estimates

Enanta Pharmaceuticals (ENTA) delivered earnings and revenue surprises of -81.08% and -20.97%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock...

1주 전 · Zacks

Regenxbio (RGNX) Beats Q2 Earnings and Revenue Estimates

Regenxbio (RGNX) delivered earnings and revenue surprises of +258.33% and +16.31%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

1주 전 · Zacks

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas (EDIT) delivered earnings and revenue surprises of +50.00% and +524.80%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

2 페이지 중 1

RenovoRx Inc. (RNXT)